JP2016520531A5 - - Google Patents

Download PDF

Info

Publication number
JP2016520531A5
JP2016520531A5 JP2016503332A JP2016503332A JP2016520531A5 JP 2016520531 A5 JP2016520531 A5 JP 2016520531A5 JP 2016503332 A JP2016503332 A JP 2016503332A JP 2016503332 A JP2016503332 A JP 2016503332A JP 2016520531 A5 JP2016520531 A5 JP 2016520531A5
Authority
JP
Japan
Prior art keywords
protein
scgb3a2
recombinant human
homodimer
intact
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016503332A
Other languages
English (en)
Japanese (ja)
Other versions
JP6513632B2 (ja
JP2016520531A (ja
Filing date
Publication date
Priority claimed from US13/843,289 external-priority patent/US20140274915A1/en
Application filed filed Critical
Publication of JP2016520531A publication Critical patent/JP2016520531A/ja
Publication of JP2016520531A5 publication Critical patent/JP2016520531A5/ja
Application granted granted Critical
Publication of JP6513632B2 publication Critical patent/JP6513632B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016503332A 2013-03-15 2014-03-16 組換えヒトセクレトグロビンの改善された使用方法 Active JP6513632B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/843,289 US20140274915A1 (en) 2013-03-15 2013-03-15 Methods of Use for Recombinant Human Secretoglobins
US13/843,289 2013-03-15
PCT/US2014/030101 WO2014145357A2 (en) 2013-03-15 2014-03-16 Improved methods of use for recombinant human secretoglobins

Publications (3)

Publication Number Publication Date
JP2016520531A JP2016520531A (ja) 2016-07-14
JP2016520531A5 true JP2016520531A5 (enExample) 2017-04-27
JP6513632B2 JP6513632B2 (ja) 2019-05-15

Family

ID=51529893

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016503332A Active JP6513632B2 (ja) 2013-03-15 2014-03-16 組換えヒトセクレトグロビンの改善された使用方法

Country Status (15)

Country Link
US (5) US20140274915A1 (enExample)
EP (1) EP2968464B1 (enExample)
JP (1) JP6513632B2 (enExample)
KR (1) KR20160011621A (enExample)
CN (1) CN105722524B (enExample)
AU (1) AU2014233116A1 (enExample)
BR (1) BR112015021265A2 (enExample)
CA (1) CA2907395A1 (enExample)
ES (1) ES2883933T3 (enExample)
IL (1) IL241418A0 (enExample)
MX (1) MX2015013091A (enExample)
RU (1) RU2662665C2 (enExample)
SG (1) SG11201507276UA (enExample)
UA (1) UA118756C2 (enExample)
WO (1) WO2014145357A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140274915A1 (en) * 2013-03-15 2014-09-18 Clarassance, Inc. Methods of Use for Recombinant Human Secretoglobins
WO2016205430A1 (en) * 2015-06-15 2016-12-22 Therabron Therapeutics, Inc. Recombinant human cc10 protein facilitates repair and protects against damage to the respiratory epithelium due to exposure to both cigarette and other smoke
WO2018178051A1 (en) * 2017-03-28 2018-10-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Scgb1a1 polymorphism for the prediction and therapy or prevention of primary graft dysfunction
WO2019143934A1 (en) 2018-01-19 2019-07-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cancer activity of scbg3a2 and lps
AU2019387570A1 (en) * 2018-11-30 2021-07-15 Apc Research Assets Llc Compositions and methods of use for secretoglobins to protect the glycocalyx via interactions with heparan sulfate proteoglycan proteins
KR20200138684A (ko) * 2020-11-17 2020-12-10 김유신 토양 파쇄기를 장착한 친환경 고온스팀 토양소독기
WO2023212398A1 (en) * 2022-04-29 2023-11-02 Apc Research Assets Llc Secretoglobins for suppression of antibody responses
CN119631983B (zh) * 2024-12-30 2025-07-22 西南医科大学 一种心脏原发性肿瘤小鼠模型的构建方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040047857A1 (en) 1997-05-28 2004-03-11 Pilon Aprile L. Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
US20030008816A1 (en) 1997-05-28 2003-01-09 Pilon Aprile L. Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
US20060281681A1 (en) * 1997-05-28 2006-12-14 Pilon Aprile L Methods and compositions for the reduction of neutrophil influx and for the treatment of bronchpulmonary dysplasia, respiratory distress syndrome, chronic lung disease, pulmonary fibrosis, asthma and chronic obstructive pulmonary disease
AU5551299A (en) 1998-08-13 2000-03-06 Trustees Of The University Of Pennsylvania, The Method of identifying proteins
US6953666B1 (en) 1998-11-06 2005-10-11 Emory University Biomarkers for oxidative stress
WO2004101824A1 (ja) * 2003-05-14 2004-11-25 Shionogi & Co., Ltd. 慢性閉塞性肺疾患の検出方法
JP2007529191A (ja) * 2003-06-26 2007-10-25 ライフセンサーズ、インク. タンパク質発現を増強し、精製する方法及び組成物
CN1886152A (zh) 2003-11-14 2006-12-27 阿尔萨公司 在药物辐射赋形剂制剂中药物氧化的最小化
US20060275794A1 (en) * 2005-03-07 2006-12-07 Invitrogen Corporation Collections of matched biological reagents and methods for identifying matched reagents
JP2007059191A (ja) 2005-08-24 2007-03-08 Kazuo Kono 照明器具駆動回路
WO2008039941A2 (en) * 2006-09-27 2008-04-03 The Government Of The Usa As Represented By The Secretary Of The Dpt. Of Health And Human Services Scgb3a2 as a growth factor and anti-apoptotic agent
US20090004684A1 (en) 2007-05-23 2009-01-01 Claudia Susanne Maier Compositions and Methods for Detection and Quantification of Protein Oxidation
KR101597391B1 (ko) 2009-10-15 2016-02-24 클라라산스, 인크. 인플루엔자 치료용 재조합 사람 cc10 단백질
RU2439569C1 (ru) * 2010-11-12 2012-01-10 Федеральное государственное учреждение "Ивановский научно-исследовательский институт материнства и детства имени В.Н. Городкова" Министерства здравоохранения и социального развития Российской Федерации Способ прогнозирования бронхолегочной дисплазии у детей с врожденной пневмонией
US20140274915A1 (en) 2013-03-15 2014-09-18 Clarassance, Inc. Methods of Use for Recombinant Human Secretoglobins

Similar Documents

Publication Publication Date Title
JP2016520531A5 (enExample)
PH12020550205A1 (en) IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
MX2023007211A (es) Anticuerpos antimiostatina y metodos de uso.
MX2020006117A (es) Integracion dirigida de acidos nucleicos.
MX2021000030A (es) Metodos y composiciones que utilizan polipeptidos variantes klotho.
MY189425A (en) Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
PE20190845A1 (es) Metodos para determinar resistencia a terapia de receptor de androgeno
PH12018502361A1 (en) Gdf15 fusion proteins and uses thereof
PH12020550240A1 (en) D-domain containing polypeptides and uses thereof
MX2017006866A (es) Pares de unión para producción de péptidos.
MX2017005774A (es) Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
WO2014202616A3 (en) Rasamsonia gene and use thereof
MX382929B (es) Polipéptido heterodimerizado.
MY192481A (en) Factor viii chimeric proteins and uses thereof
MX2017010880A (es) Variantes de polipéptidos para el clivaje de la toxina fusario, aditivo que contiene las mismas, uso de las mismas, y método para el clivaje de las toxinas fusario.
PH12020550927A1 (en) Therapeutic enzyme fusion protein having novel structure and use thereof
PH12013500715A1 (en) Anticancer fusion protein
PH12020500054A1 (en) Novel therapeutic enzyme fusion protein and use thereof
WO2016130628A8 (en) Griffithsin mutants
WO2014170460A3 (en) Method for the production of collagen proteins derived from marine sponges and an organism able to produce said proteins
NZ724196A (en) Uti fusion proteins
JP2016519950A5 (enExample)
MX2015009867A (es) Mutantes del factor x.
WO2018081350A8 (en) SIGNAL POLYPEPTIDE FOR ENHANCED PROTEIN SECRETION
WO2019103512A3 (ko) 목적 단백질의 발현 효율을 증진시키기 위한 신규한 펩타이드 및 이를 포함하는 융합 단백질